FORM 4
[ X ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

BERNS PAUL L 		2. Issuer Name and Ticker or Trading Symbol

ALLOS THERAPEUTICS INC [ ALTH ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
Chief Executive Officer
(Last)          (First)          (Middle)

11080 CIRCLEPOINT ROAD, SUITE 200 		3. Date of Earliest Transaction (MM/DD/YYYY)

9/4/2012
(Street)

WESTMINSTER, CO 80020
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   9/4/2012     U    1233323   (1) (2) D $1.82   0   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
( 1)  The Reporting Person tendered these shares pursuant to that certain Agreement and Plan of Merger by and among the Issuer, Spectrum Pharmaceuticals, Inc. and Sapphire Acquisition Sub, Inc., dated April 4, 2012 (the "Merger Agreement"), and the Tender and Voting Agreement, dated April 4, 2012, by and among Spectrum Pharmaceuticals, Inc., Sapphire Acquisition Sub, Inc. and the Reporting Person.
( 2)  Includes 1,042,957 restricted stock units (an "RSU") awarded to the Reporting Person under the Issuer's 2008 Equity Incentive Plan tendered in exchange for a payment of $1.82 per underlying share of common stock, net of withholding, plus one contingent value right for each underlying share (a "CVR") pursuant to the tender offer described in the Tender Offer Statement on Schedule TO filed by Sapphire Acquisition Sub, Inc. with the Commission on April 16, 2012, as amended (the "Tender Offer"). Each RSU that was outstanding immediately prior to the Acceptance Time (as defined in the Merger Agreement) was canceled, with the holder of such RSU receiving in consideration of such cancellation, the payment described above.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
BERNS PAUL L
11080 CIRCLEPOINT ROAD
SUITE 200
WESTMINSTER, CO 80020

Chief Executive Officer

Signatures
/s/ David C. Clark, Attorney-in-Fact for Paul L. Berns 9/5/2012
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Allos Therapeutics, Inc. (MM) Charts.
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Allos Therapeutics, Inc. (MM) Charts.